This note summarises the principal steps for establishing a pharmaceuticals company operating in England and Wales. It is written from the perspective of a corporate and regulatory adviser located at our London office: Holborn Gate, 330 High Holborn, London, WC1V 7QH, England. The guide focuses on incorporation, regulatory authorisations and practical compliance tasks that typically precede commercial manufacture, import, distribution or sale of human medicines.

Incorporation and initial regulatory registrations

Most investors operate through a private company limited by shares. Basic steps include incorporation at Companies House, registering for corporation tax and VAT with HM Revenue & Customs (HMRC), and ensuring an appropriate UK registered office address. If your business will import or export, obtain an EORI number and ensure customs processes are established.

Medicines-specific licences and authorisations

Commercial manufacture, wholesale distribution and marketing of human medicines in Great Britain require specific MHRA permissions. Common authorisations include:

• Manufacturer’s Authorisation (including compliance with Good Manufacturing Practice (GMP));
• Wholesale Distribution Authorisation (WDA(H)) for supply and distribution activities;
• Marketing Authorisation (product licence) for each medicinal product intended for sale in Great Britain;
• Special licences where applicable for imports, clinical trials and unlicensed specials.

Organisations must also demonstrate appropriate quality systems, batch release mechanisms and access to a Qualified Person (QP) for human medicines where required by the regulations.

Note on Northern Ireland: regulatory arrangements for Northern Ireland differ under the Protocol. Products placed on the market in Northern Ireland may require compliance with EU-derived procedures in addition to UK arrangements.

Permits, premises and health & safety compliance

Premises used for manufacture, batch release or storage must meet MHRA standards and be capable of passing inspection. Other regulatory matters to address include:

• Environmental permits for pharmaceutical effluent or waste where required (Environment Agency);
• Health and safety compliance including COSHH risk assessments and HSE reporting obligations;
• Controlled drugs licensing and record-keeping under the Misuse of Drugs Regulations and Home Office requirements if handling controlled substances;
• Insurance, employment and data-protection obligations as relevant to operations.

Practical checklist

• Incorporate company with Companies House; appoint registered office.
• Register for corporation tax and VAT with HMRC; obtain EORI for trade.
• Prepare premises and quality management system to meet GMP requirements.
• Apply to the MHRA for Manufacturing Authorisation and/or WDA(H) as needed.
• Secure marketing authorisations or rely on appropriate import/specials routes for products.
• Assess controlled drugs requirements and apply to the Home Office if applicable.
• Ensure environmental permits and HSE/COSHH compliance are in place.

Operational considerations

Beyond authorisations, companies must maintain pharmacovigilance processes, product safety reporting, compliant labelling and leaflets, and robust supply‑chain and distributor agreements. Post-Brexit trade flows require careful planning of import/export documentation and parallel supply strategies between Great Britain and Northern Ireland.

Jurisdiction and sources

• Medicines and Healthcare products Regulatory Agency (MHRA)
• Companies House
• HM Revenue & Customs (HMRC)
• Home Office (controlled drugs licensing)
• Environment Agency (environmental permits)
• Health and Safety Executive (HSE)
• Human Medicines Regulations 2012 (legislation.gov.uk)

For complex product portfolios, cross-border commercial strategies or regulatory interaction with the MHRA and other authorities, early engagement with experienced regulatory, corporate and compliance advisers is recommended.

General information only; not legal advice and not a substitute for advice on a particular matter.